SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?


To: Paul Senior who wrote (38678)8/3/2010 12:50:11 PM
From: Madharry  Read Replies (2) | Respond to of 78476
 
Buying msft for the first time ever at $26.02. also note ttt offering rights to shareholder of record as of 8/06/10. I think today is the last day to buy if you are interested. I bought a few more shares as do far Mr. Smith has treated my portfolio very well. ttt is the old khd which Mr. Smith wants to make into a base metal royalty company i believe. there is an article on this in seeking alpha.



To: Paul Senior who wrote (38678)8/3/2010 3:25:09 PM
From: Spekulatius  Read Replies (2) | Respond to of 78476
 
re SNY - i have no problems with acquisition per say but GENZ does not seem like a good fit for SNY
First of all GENZ specialty biologics do not fit into SNY existing portfolio as I see it. Furthermore I do not think that GENZ incredible expensive orphan drugs (for Gaucher and such) are unassailable either if political powers decide otherwise and open the door for biological drug generics for example. I think this would be much easier to do if a company offering such expensive offering (we are talking about 100k/ patient and year!) is owned by a foreign company. Headline " French company charges 100k$/ year for single drug -medicare pays..."

I could see if SNY would acquire a emerging market generics company or a vaccine upstart, but GENZ? I probably sell the remainder of my shares as well, selling half is not really a solution if you don't have confidence.